The anticipated data from the BEACON study, which evaluates briquilimab for chronic spontaneous urticaria, is a significant upcoming catalyst for Jasper Therapeutics. The study’s outcomes, expected in ...

Jasper has received regulatory clearance to enroll participants in a 180mg dose cohort as part of the study and expects to present full data from the SPOTLIGHT study in the first half of 2025.

The firm's endorsement follows Jasper's recent presentation of six-week data from the SPOTLIGHT study, which is focused on the efficacy of briquilimab in treating chronic inducible urticaria (CIndU).

In alignment with the Company’s clinical development plan, Jasper has obtained regulatory clearance to enroll a 180mg dose cohort (n=12) in the SPOTLIGHT study. Jasper expects to present full ...

“We achieved several significant milestones in our mast cell development programs in recent months, highlighted by positive initial data from our SPOTLIGHT study in CIndU,” said Ronald Martell, ...

(RTTNews) - Jasper Therapeutics (JSPR) reported preliminary data from the ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria or symptomatic ...

Jasper Therapeutics (JSPR) announced that it is commencing an open-label extension study in chronic urticarias that will roll over patients from the BEACON and SPOTLIGHT studies upon completion of ...

On Monday, Jasper Therapeutics (NASDAQ:JSPR) received a reaffirmed Buy rating from TD Cowen, following promising initial data from a clinical trial. The study in question, Ph1b/2a SPOTLIGHT, evaluated ...

In alignment with the Company’s clinical development plan, Jasper has obtained regulatory clearance to enroll a 180mg dose cohort (n=12) in the SPOTLIGHT study. Jasper expects to present full ...

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has announced preliminary results from its ongoing SPOTLIGHT Phase 1b/2a clinical trial, which is investigating the use of briquilimab for the treatment of ...

Briquilimab was well tolerated in the study, with no serious adverse events (SAEs) and no grade 3 or higher adverse events (AEs) reported. In alignment with the Company's clinical development plan, ...